E

Alternative cell therapy approaches to tackling cancer

How can we go about improving cell therapy approaches?

March 26, 2020
E

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020
E

Novel Targets and Agents – Part 2

In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…

March 20, 2020
E

How to tackle immune suppression in multiple myeloma

Tackling immune suppression in hematologic malignancies may improve outcomes with existing regimens

March 18, 2020
E

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020
E

Lining up multiple approaches in AML

Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.

January 23, 2020
E

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020
E

Lining up new developments in the treatment of GVHD

Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.

January 13, 2020
E

The Evolving Competitive Landscape for TIM-3

TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.

January 8, 2020
E

Novel agents and targets – Part 1

Some novel targets, new agents and some twists in the tale to consider in hematologic malignancies

December 19, 2019
E

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019
E

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019
E

Friday Scientific Workshops are the Perfect Warm-Up act to ASH19

Science Friday at ASH19 with a look at various lymphoma and myeloma developments

December 7, 2019
E

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019
E

9 up and coming non-T cell based immunotherapy approaches

Non-T cell based immunotherapies that could be promising in hematologic malignancies

November 21, 2019
E

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019
E

New developments in targeting the B cell receptor pathway

It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!

November 7, 2019